ReviewJournal of neurology2017
An update on migraine: current understanding and future directions.
Review in Journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 6 syntheses or guidelines pooled it, 150 citations in OpenAlex.
- Comparative Efficacy and Acceptability of Noninvasive Brain Stimulation for Migraine: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.Brain and behavior · 2026Pooled it
- Living with migraine: A meta-synthesis of qualitative studies.Frontiers in psychology · 2023Pooled it
- Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis.Journal of oral & facial pain and headache · 2022Pooled it
- Cortical Thickness in Migraine: A Coordinate-Based Meta-Analysis.Frontiers in neuroscience · 2020Pooled it
- Giving Researchers a Headache - Sex and Gender Differences in Migraine.Frontiers in neurology · 2020Pooled it
- CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis.Brain and behavior · 2019Pooled it
- Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study.BMC neurology · 2023Trial
- The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN).Journal of neurology · 2023Trial
- Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial.The journal of headache and pain · 2018Trial
- Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial.The journal of headache and pain · 2018Trial
- Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study.Neurology · 2018Trial
- Design and Evaluation of Multi-Electrode Configurations for Transcutaneous Frontal Nerve Activation.Biosensors · 2026Article
- Migraine in the Corporate Sector: Prevalence, Risk Factors, Job Efficiency Impact, and Management Strategies.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Oxidative Stress in Migraine-Effect or Cause?Genes · 2026Review
- Incorporating Therapeutic Education and Exercise in Migraine Management: A Biobehavioral Approach.Journal of clinical medicine · 2024Review
- Review
- Beyond Pain: The Effects of OnabotulinumtoxinA Therapy on Sensitization and Interictal Symptoms in Chronic Migraine.Toxins · 2024Review
- Association between risk factors and migraine in Pakistani females.BMC women's health · 2023Article
- Migraine: from pathophysiology to treatment.Journal of neurology · 2023Review
- Glia Signaling and Brain Microenvironment in Migraine.Molecular neurobiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a common brain disorder with high disability rates which involves a series of abnormal neuronal networks, interacting at different levels of the central and peripheral nervous system. An increase in the interest around migraine pathophysiology has allowed researchers to unravel certain neurophysiological mechanisms and neurotransmitter involvement culminating in the recent development of novel therapies, which might substantially change the clinical approach to migraine patients. The present review will highlight the current aspects of migraine pathophysiology, covering an understanding of the complex workings of the migraine state and the brain regions responsible for them. We will further discuss the therapeutic agents which have appeared in the most recent years for migraine care, from calcitonin gene-related peptide (CGRP) receptor antagonists, gepants; through serotonin 5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.